This article is more than 5 years old. Information may no longer be current.

Neurotech initiates two phase 2/3 trials of retinitis pigmentosa treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LINCOLN, R.I. — Neurotech Pharmaceuticals has begun enrollment for two phase 2/3 clinical trials of NT-501, a product based on the company's Encapsulated Cell Technology for treating vision loss associated with retinitis pigmentosa, the company announced in a press release.

NT-501 is an intraocular polymer implant that contains human retinal epithelial cells genetically modified to secrete ciliary neurotrophic factor (CNTF). The implant is designed to provide continuous, sustained release of CNTF intraocularly.

The two trials are randomized, double-masked, sham-controlled, dose-ranging studies evaluating the efficacy and safety of the CNTF implant. One trial will include patients with an earlier disease stage, and the other trial involves patients with later stage retinitis pigmentosa, according to the release.